Diabetic Dermopathy and Poor Glycemic Control among Diabetic Patients in Sulaimaniyah, Kurdistan, Iraq
DOI:
https://doi.org/10.56056/amj.2022.168Keywords:
Diabetes mellitus, diabetic dermopathy, angiopathic manifestations, pretibial spots, glycemic controlAbstract
Background and objectives: Diabetes mellitus is the commonest endocrine disorder among the general population. Shin spots or diabetic dermopathy is the foremost common cutaneous sign of diabetes mellitus. Sporadic shin spots may occur in non-diabetic people. However, 4 or more spots are highly specific of microangiopathy in diabetics and may indicate a poor glycaemic control. This study was done to evaluate prevalence of diabetic dermopathy among a group of Iraqi diabetic patients living in Sulaimaniyah, region of Kurdistan and its correlation with the state of diabetic control.
Methodology: This is a cross sectional study included 500 diabetics whom were diagnosed according to standard diagnostic criteria. Demographic and clinical features were obtained such as age and sex besides duration and treatment of the disease as well as cutaneous manifestations of diabetic dermopathy.
Results: In regard to the state of glycemic control, 208 patients (41.6%) were poorly-controlled, while 292 (58.4%) were well-controlled. Overall, diabetic dermopathy was observed in 109 (21.8%) patients (males, n=70; 64.2%, females, n=39; 35.8%). In the poorly-controlled group, 98 (89.9%) patients had diabetic dermopathy while only 11 (10.1%) patients of well-controlled diabetics had DD. This difference was statistically significant.
Conclusion: diabetic dermopathy was more prevalent among poorly-controlled diabetics. Although diabetic dermopathy is a subtle clinical sign, it could be used as a marker of poor glycaemic control and hence a clue to the possible existence of serious microangiopathic changes.
Downloads
References
Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol 2003; 4(5):315-31. doi: 10.2165/00128071-200304050-00003. PMID: 12688837
Piero MN, Nzaro GM, Njagi JM. Diabetes mellitus–a devastating metabolic disorder. Asian J Biomed Pharmaceut Sci 2014; 4(40):1-7.
Diabetic Dermopathy. 2019 Available from https://www.skinsight.com/skin-conditions/adult/diabetic-dermopathy
Craft N, Fox LP, Goldsmith LA, Tharp MD. Clinical Information and Differential Diagnosis of Diabetic Dermopathy. 2019 Available from https://www.visualdx.com/visualdx/diagnosis/diabetic-dermopathy?moduleId=7&diagnosisId=51430
George S, Walton S. Diabetic dermopathy. Br J Diabetes Vasc Dis 2014; 14: 95-7.
Sagi L, Trau H. The Koebner phenomenon. Clin Dermatol 2011; 29(2):231-6.
Farmer A. Use of HbA1c in the diagnosis of diabetes. BMJ. 2012; 345: e7293.
Jedlowvski PM, Te CH, Segal RJ, Fazel MT. Cutaneous Adverse Effects of Diabetes Mellitus Medications and Medical Devices: A Review. Am J Clin Dermatol. 2019; 20:97–114.
Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019.Diabetes Care. 2019; 42(1): S13-S28.
McCash S, Emanuel PO. Defining diabetic dermopathy. J Dermatol 2011; 38:988-92.
Brugler A, Thompson S, Turner S, Ngo B, Rendell M. Skin blood flow abnormalities in diabetic dermopathy. J Am Acad Dermatol 2011; 65:559-63.
Wigington G, Ngo B, Rendell M. Skin blood flow in diabetic dermopathy. Arch Dermatol 2004; 140: 1248-50.
Alromi JF, Taha AY, Al-Zacko SM. Potassium Titanyl Phosphate (KTP) 532 nm Laser for Treatment of Facial Vascular Lesions: a Prospective Analysis of 27 Cases. Egypt J Surg. 2018; 37: 209-216.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Ali Mozan Dhahir Elethawi
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in AMJ (The Scientific Journal of Kurdistan Higher Council of Medical Specialties )is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0)